

**Freedom of Information:
Asthma Patients - Treatment - 28/01/2019**

Request:

- 1: In your trust, in the past 3 months [latest 3 months available], how many asthma patients aged 18 and over have been treated [with a drug]?
- 2: How many paediatric asthma treated patients [aged 6-17] have been treated in the last 3 months?
- 3: How many severe asthmatic patients [BTS guidelines, step 4 or 5] have been treated in the last 3 months?
- 4: How many patients have been treated in the last 3 months with:
Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]
Other [Please state]
- 5: How many paediatric patients have treated in the last 3 months with Xolair/omalizumab?
- 6: Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs; ALL patients – not asthma patients (question not very clear)
Ocreotide
Lanreotide
Pasireotide
Pegvisomant

Response:

- 1: 2962
- 2: 194
- 3: 22

- 4: Omalizumab [Xolair] – 21
Mepolizumab [Nucala] – 0
Reslizumab [Cinqaero] – 0
Benralizumab [Fasenra] – 0
Other [Please state] – 0
- 5: 1
- 6: Ocreotide – 31 patients Apr – Dec 2019
Lanreotide – 7 patients Apr – Dec 19
Pasireotide – 0
Pegvisomant – 0